We combined the data for the TP53 mutation status of a large cohort of cancer cell lines (including pediatric entities such as medulloblastoma, neuroblastoma and Ewing sarcoma) from the Cancer Cell Line Encyclopedia (CCLE, Broad Institute, Cambridge, MA, USA) and the DepMap portal with PRIMA-1 sensitivity data obtained from the CTD2 portal (Broad Institute, Cambridge, MA, USA, CTRP v2, 2015) [49,56,57]. This evidence concerns the gene TP53 and neuroblastoma.